Factors associated with deferral or non‐performance of an organized breast cancer screening program during the COVID‐19 pandemic in France
Cancer Medicine · 2024
DOI: 10.1002/cam4.7444 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Cancer Medicine, 2024. Verfasst von Jean Papadacci Stephanopoli und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Medicine, Université de Reims Champagne-Ardenne, Reims, Marne, France. Hauptthemen laut MEDLINE: Breast Neoplasms, Early Detection of Cancer, Mammography. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Delays in detection and treatment of breast cancer can lead to increased mortality. To date, participation in organized breast cancer screenings (OBCS) has been suboptimal worldwide. The objective of this study was to investigate the factors associated with deferral or non‐performance of mammography during the COVID‐19 pandemic for women who had previously participated in OBCS.
Methods
A retrospective observational study was conducted on a cohort of 6282 women from the Aube Department of France, who were invited to an OBCS in 2020. Participants were divided into women who promptly underwent screening after receiving an invitation (between 22 and 25 months elapsed since the last mammogram), women who underwent late screening (≥26 months since the last mammogram), and those who were never screened. Data were collected from a self‐reported questionnaire. Comparative and multivariable analyses modeling the probability of each type of attendance were performed using these data.
Results
In total, 2301 women (aged 50–74 years) returned a valid questionnaire. Compared to women who promptly underwent mammography, non‐ and late‐screening participants were younger, had less frequent gynecological follow‐up and a less frequent history of colorectal cancer screening. Women with higher education status and those residing in socially disadvantaged areas were more likely to attend late.
Conclusion
The absence of regular gynecological follow‐up and the absence of colorectal cancer screening were significant factors associated with deferral of or non‐attendance at OBCS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of General Medicine, Université de Reims Champagne-Ardenne, Reims, Marne, France.
- Médecine générale, Maison de Santé Pluriprofessionnelle de la Forêt d'Orient, Piney, Aube, France.
- Comité Universitaire de Ressources pour la Recherche en Santé,, Université de Reims Champagne-Ardenne, Reims, Marne, France.
- CRCDC, Centre Régional de Coordination des Dépistages des Cancers du Grand Est, Troyes, Aube, France.
- Department of Gynecology and Obstetrics, Centre Hospitalier Universitaire de Reims, Université de Reims Champagne-Ardenne, Reims, Marne, France.
- Department of Public Health and Performance, Centre Hospitalier de Troyes, Troyes, France.
ORCID-Profile: Cécile Barbaret, Stéphane Sanchez
Zitieren
APA
Stephanopoli, J. P., Bouazzi, L., Guerbaz-Sommi, M., Graesslin, O., Hurtaud, A., Ilardo, S., Chrusciel, J., Barbaret, C., Bertrand, C., & Sanchez, S. (2024). Factors associated with deferral or non‐performance of an organized breast cancer screening program during the COVID‐19 pandemic in France. Cancer Medicine. https://doi.org/10.1002/cam4.7444
Vancouver
Stephanopoli JP, Bouazzi L, Guerbaz-Sommi M, Graesslin O, Hurtaud A, Ilardo S, et al. Factors associated with deferral or non‐performance of an organized breast cancer screening program during the COVID‐19 pandemic in France. Cancer Medicine. 2024. doi:10.1002/cam4.7444
BibTeX
@article{Stephanopoli2024,
author = {Stephanopoli, Jean Papadacci and Bouazzi, Leila and Guerbaz-Sommi, Myriam and Graesslin, Olivier and Hurtaud, Aline and Ilardo, Salvatore and Chrusciel, Jan and Barbaret, Cécile and Bertrand, Camille and Sanchez, Stéphane},
title = {Factors associated with deferral or non‐performance of an organized breast cancer screening program during the COVID‐19 pandemic in France},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.7444}
}
EUVIMED